MDXG MiMedx Group Inc.

MIMEDX to Sponsor and Attend Symposium on Advanced Wound Care (SAWC) Fall

MIMEDX to Sponsor and Attend Symposium on Advanced Wound Care (SAWC) Fall

To Present Six Posters Featuring the Company’s Latest Product Innovations

MARIETTA, Ga., Sept. 03, 2025 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced its schedule for the Symposium on Advanced Wound Care (SAWC) Fall meeting taking place September 3-6 in Las Vegas, NV. SAWC remains a premier event for clinicians and industry professionals to explore the latest clinical evidence and innovations in advanced wound care. The Company will showcase its leading advanced wound care portfolio in the exhibit hall at booth 511.

Sponsored Lunch Symposium

Title: Change is Inevitable: Mastering the Art of Wound Healing in an Evolving Landscape

Date: Thursday, September 4, 2025

Time: 11:40 – 1:10 p.m. PDT

Faculty: Paul Kim, DPM, MS, FACFAS; Nicolas Mouawad, MD, MPH, MBA, DFSVS, FRCS, FACS, RPVI; Scott Boynton, DPM, FACFAS

Description: Wound care is constantly evolving, and clinicians must adapt to an ever-changing landscape of patient complexities and clinical challenges. In this dynamic symposium, Drs. Paul Kim, Nicolas Mouawad, and Scott Boynton will discuss advanced treatment approaches that support clinicians in optimizing wound healing across diverse patient populations and present challenging real-world cases.

Accepted Poster Presentations

The Company is pleased to announce that six clinical and scientific posters have been accepted and will be on display in the poster hall.

  • Therapeutic Potential of Amniotic Tissue in Promoting Pigment Restoration During Wound Healing
  • Bovine Extracellular Matrix Particulate Modulates Fibroblast Cellular Activities Supportive of Wound Management
  • Characterization of PURION® Processed Dual Layer Chorion Allograft
  • Amniotic Membrane Allografts promote re-epithelialization in vitro via cJUN Mediated Mechanism
  • Adjunctive Dehydrated Human Amnion Chorion Membrane Usage for Pressure Injuries in the Post-Acute Care Setting
  • Reconstruction Following Mohs Surgery with a Placental Allograft: A Cost-Effectiveness Analysis  

About MIMEDX

MIMEDX is a pioneer and leader focused on helping humans heal. With more than a decade of helping clinicians manage chronic and other hard-to-heal wounds, MIMEDX is dedicated to providing a leading portfolio of products for applications in the wound care, burn, and surgical sectors of healthcare. The Company’s vision is to be the leading global provider of healing solutions through relentless innovation to restore quality of life. For additional information, please visit .

Contact:

Matt Notarianni

Investor Relations

470-304-7291



EN
03/09/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on MiMedx Group Inc.

 PRESS RELEASE

MIMEDX Announces Publication in the Journal of Inflammation Focused on...

MIMEDX Announces Publication in the Journal of Inflammation Focused on Immunomodulatory Effects of Purion® Processed Human Amniotic Membrane Allografts In Vitro Study investigates the influence of MIMEDX DHACM and LHACM products on inflammatory response, which supports the healing cascade and tissue repair MARIETTA, Ga., Dec. 19, 2025 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced the latest addition to its industry-leading body of scientific and clinical evidence supporting the use of its dehydrated human amnion chorion membrane (DHACM...

 PRESS RELEASE

MIMEDX Provides Update on EPIEFFECT® Randomized Controlled Trial

MIMEDX Provides Update on EPIEFFECT® Randomized Controlled Trial Publication of Interim Results and Presentation at Recent Industry Event Demonstrate Clinical Benefit Associated with Use of EPIEFFECT When Compared to Standard of Care (“SOC”) Publication Adds to Large Compendium of Evidence for MIMEDX’s Leading Product Portfolio Trial Enrollment Ongoing MARIETTA, Ga., Nov. 13, 2025 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced the publication of interim results from its CAMPAIGN trial, a randomized controlled trial (“RCT”) designed to...

 PRESS RELEASE

MIMEDX to Participate in Upcoming Investor Conferences

MIMEDX to Participate in Upcoming Investor Conferences MARIETTA, Ga., Nov. 10, 2025 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that members of its senior management will participate in the following investor conferences: Craig-Hallum 16th Annual Alpha Select Conference | New York, NYTuesday, November 18, 20251:1 sessions Canaccord MedTech, Diagnostics and Digital Health & Services Forum | New York, NYThursday, November 20, 20251:1 sessions Investors interested in meeting with senior management at these events may contact their resp...

 PRESS RELEASE

MIMEDX Comments on CY 2026 Medicare Physician Fee Schedule Final Rule

MIMEDX Comments on CY 2026 Medicare Physician Fee Schedule Final Rule Company is Well Positioned to Continue to Compete and Grow MARIETTA, Ga., Nov. 03, 2025 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today commented on the Centers for Medicare and Medicaid Services (“CMS”) release of the CY 2026 Physician Fee Schedule (“PFS”) final rule, which was published on Friday. “Over the last several years, we have actively engaged with numerous stakeholders to advocate for much-needed reform of the Medicare reimbursement system for skin substitutes. CMS i...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch